Pre-Approval
|
Contact
VRDL.Submittal@cdph.ca.gov for pre-approval.
Please provide all of the supplemental information requested for a complete and accurate assessment.ā
|
Supplemental Information Requested
|
Requested:
-
āTravel location(s)
- Please note any travel to an area with documented or suspected Oropouche virus circulation within two weeks of initial symptom onset (as patients may experience recurrent symptoms).
-
Travel dates
-
Symptom onset date
- Please include earliest onset date. If the patient experienced a relapse, then please list 1) date of initial symptom resolution, and 2) date of recurrence.
-
Symptoms
- Please list all known symptoms associated with this illness. Please note whether the patient experienced any abrupt onset of fever, headache, and any of the following symptoms:
- āmyalgia, arthralgia, photophobia, retroorbital/eye pain, or signs and symptoms of neuroinvasive disease (e.g., stiff neck, altered mental status, seizures, limb weakness, or cerebrospinal fluid pleocytosis)
-
Co-morbidities
-
Immunocompromising medications
-
Pregnancy status
- āPlease include gestational age or estimated date of delivery
-
Dates and results of previous testing for other arboviruses, in particular dengue virus.
-
All specimen type(s) available
|
Submittal Formāā
|
Specimens must be accompanied with a hard copy of the completed VRDL General Purpose Specimen Submittal Formāā (PDF) or a form generated in the VRDL Lab Web Portal. |
| Methodology (Commercial Test Name or Laboratory Developed Test (LDT)) |
Plaque Reduction Neutralization Test (LDT) (Surveillance use only)
Please note that specimens received at VRDL will be split: 1 mL will be sent to CDC for molecular and/or serological testing.ā
|
| Reflex Testing |
None
|
| Acceptable Specimen Type(s) and Collection Method |
āHuman specimens:
-
āSerum:
- āāāPlain Red-Top Tubes: serum collected in plain, red-top tubes must be separated and transferred to sterile, screw-cap tubes for storage and transport.
- āāāSerum Separator Tubes (SST): SST may be transported after centrifugation.
-
āCSF: Collect CSF in sterile, screw-cap tubes
|
Minimum Volume Requestedā
|
- āāSerum: 2 mL
- CSF: 2 mL
|
| Transport Medium (if applicable) |
Not Applicable |
| Specimen Labeling |
Each specimen tube must be labeled with at least two unique patient identifiers, e.g., patient full name and date of birth.
|
| Storage & Preservation of Specimen / Shipping Conditions |
- āSeparated Serum: Refrigerate or freeze separated serum promptly after collection.
- Serum Separator Tubes: Refrigerate, do not freeze.
- CSF: Refrigerate or freeze CSF promptly after collection.ā
Ship refrigerated specimens to VRDL on cold packs. Ship frozen specimens to VRDL on dry ice.
|
| Shipping Instructions |
Work with your local public health department to ensure samples are packaged according to instructions for Biological Substance ā Category B (UN 3373) shipment.
Ship specimens and a hard copy of the completed submittal forms to:
āCDPH VRDL
ATTN: Specimen Receiving
850 Marina Bay Parkway
Richmond, CA 94804
Phone: 510-307-8585
|
| Turnaround Time |
16 Business Days |
| Limitations |
āPRNT might be performed with multiple viruses that are closely related and/or geographically co-circulating. Traditionally, where neutralizing ā
antibodies are detected for more than one closely related virus, a four-fold difference in titer is presumed to indicate the identity of the exposure; however, due to the possibility of an anamnestic antibody response, and the fact that not all possible viruses can be tested, specimens are screened at low dilutions and results are reported as antibody detected or not detected. Reactivity for more than one closely related virus is reported as evidence of undifferentiated infection at the genus level.
Laboratory results with clinical and environmental correlation must be used together with current case definitions to confirm or rule out cases.
|
| Additional Information |
CDC Interim Guidance for Health Departments on Testing and Reporting for Oropouche Virus Disease āā
A convalescent specimen is recommended to help determine recency of infection. When submitted separately, be sure to identify the previously submitted specimen by the VRDL accession number so that the acute and convalescent specimens may be linked, tested to endpoint and interpreted as a pair.
|
| VRDL Points of Contact |
Medical and Epidemiology Liaisons: (510) 307-8585 or VRDL.submittal@cdph.ca.govāāāā
|